What cultivated beef is
Cultivated beef is beef grown from bovine cells outside the animal. A small cell sample is taken from a live cow, the cells are multiplied in a bioreactor, and they are then matured into muscle and, in some designs, fat. The result is real animal tissue, not a plant-based analogue, and it belongs in the broader field of cultivated meat.
The scientific case was laid out in a 2014 paper from Maastricht University. Its author described culturing beef from bovine skeletal muscle stem cells as feasible but still under development. The aim was a beef mimic with the taste, texture and appearance of livestock beef, and equal nutritional value, with protein and fat content still needing optimisation.
Scale is the second hurdle named in that paper, since current small bioreactors must be modified to reach the largest possible volume. The same author considered consumer acceptance promising from initial data, while calling for detailed studies of psychological barriers. Those themes, cell biology, reactor engineering and acceptance, still define the field and frame the rest of this page.
Production: cells, media and scaffolds
Cultivated beef production starts with the choice of cell. A 2026 scoping review names muscle satellite cells, mesenchymal stem cells and fibro-adipogenic progenitors as the main sources, and calls satellite cells the most suitable. Expansion is limited, because repeated passaging causes senescence and drift in cell behaviour, which later impairs fusion into muscle fibres.
Culture medium is the dominant cost. Fetal bovine serum carries ethical, regulatory and price problems, and its poorly defined composition complicates safety assessment. Serum-free, chemically defined media are being developed, yet keeping growth and differentiation performance is hard. Media tuned for growth tend to suppress differentiation, so producers trade yield against tissue quality.
Structure needs support. Scaffolds must be porous for oxygen and nutrient exchange and edible or removable. Options include fibrin, collagen and zein, polysaccharides such as cellulose and alginate, and plant or fungal materials. Aleph Farms describes a plant protein matrix of soy and wheat. Decellularisation detergents, solvents and cross-linkers raise their own safety questions that reviewers must address.
Cultivated beef nutrition
Cultivated beef nutrition is still being characterised, and the data are mixed. The review uses a conventional reference of 100 grams of cooked beef with 25.93 grams of protein, 15.13 grams of lipid, 2.15 milligrams of iron, 5.84 milligrams of zinc and 84 milligrams of cholesterol. Cultivated products are measured against that yardstick.
Results so far are uneven. A cell-sheet product held 6.3 percent protein by wet weight against 11.3 percent for beef, but on a dry-weight basis it reached 50.6 percent against 28.8 percent, which the authors attribute to high water content. A commercial cultivated chicken was reported at 16 grams of protein per 100 grams, like conventional chicken.
Fat is another gap. Many prototypes lack adipose tissue, which lowers fat content and may hurt flavour, although cultured fat can be tuned to reduce saturated fats. One bovine study found a fatty acid profile similar to beef tallow. Direct digestibility comparisons are limited, and in vivo data are scarce. The sister page on cultivated fat covers that fraction.
Cultivated beef regulation by market
Cultivated beef regulation differs by market. In Israel, the Ministry of Health issued a No Questions letter for Aleph Cuts, which the company calls the first approval for cultivated beef anywhere. The cells come from a Black Angus cow, are neither modified nor immortalised, and grow without fetal bovine serum or antibiotics. Approval carried labelling directions and a plant inspection.
Singapore treats cultivated meat as a novel food that needs pre-market assessment covering toxicity, allergenicity, production method safety and dietary exposure. Applicants complete a self-assessment checklist for cell-based food, pay a fee of 1,750 Singapore dollars and expect about nine to twelve months for review. A change of cell line or culture medium component can require approval again.
Elsewhere, no cultivated beef is cleared in the United States. FDA’s inventory lists three chicken files, one pork fat file and one salmon file. In the EU, Gourmey filed for cultivated duck in July 2024 and Mosa Meat for cultivated beef fat in January 2025. Australia and New Zealand approved cultured quail in 2025 and require the label wording cell-cultured.
Applications and formats
Early products are whole cuts and restaurant dishes. Aleph Farms served a petit steak to diners in Israel, and its approval covers a range it calls Aleph Cuts. Scaffolds must be porous for nutrient and oxygen exchange, which shapes how thick a cut can be and which formats are practical to produce.
Hybrid formats are the practical bridge. Cell-grown beef can be blended into products built on textured pea protein, where the plant component supplies bulk and structure and the cell fraction adds flavour and animal protein. The same logic applies to mycoprotein bases, and the page on mycoprotein shows how fungal texture can carry such blends.
Chicken dominates the regulatory record so far, which makes it the nearest point of comparison for processing and labelling. The page on cultivated chicken shows what regulators have already reviewed. Seafood follows a similar path, covered under cultivated seafood, and each species needs its own safety dossier because cells and media differ.
Sourcing, supply and evaluation
Supply today is pilot scale, so buyers deal with development partners rather than commodity suppliers. Evaluation starts with the regulatory position in the target market, then moves to cell source, medium composition, scaffold, and the evidence behind composition and safety claims. Environmental benefits cited for the sector remain largely projections from life cycle models, not data from large plants.
Technical questions to ask include protein and fat per 100 grams on a wet basis, water content, texture measurements after cooking, and the stability of the cell line over repeated passaging. A buyer should also confirm which media ingredients are used, since serum, antibiotics and recombinant growth factors each carry different regulatory and labelling implications.
Because approvals are specific to the applicant and the process, switching to another producer is not simply a purchasing decision. A different cell line or medium can mean a new assessment. Product developers planning launches should model long lead times, keep conventional or plant-based fallbacks ready, and treat each market’s labelling wording as a design constraint from the start.